Progyny (NASDAQ: PGNY) is one of 27 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it weigh in compared to its peers? We will compare Progyny to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, earnings, risk and valuation.
Risk & Volatility
Progyny has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Progyny’s peers have a beta of 7.07, suggesting that their average share price is 607% more volatile than the S&P 500.
81.5% of Progyny shares are owned by institutional investors. Comparatively, 43.2% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 33.3% of Progyny shares are owned by company insiders. Comparatively, 26.4% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a summary of recent ratings and target prices for Progyny and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Progyny presently has a consensus price target of $43.40, indicating a potential downside of 32.19%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 19.40%. Given Progyny’s peers higher possible upside, analysts plainly believe Progyny has less favorable growth aspects than its peers.
This table compares Progyny and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Progyny and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Progyny||$344.86 million||$46.46 million||355.56|
|Progyny Competitors||$1.94 billion||$96.17 million||42.17|
Progyny’s peers have higher revenue and earnings than Progyny. Progyny is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Progyny beats its peers on 8 of the 13 factors compared.
Progyny Company Profile
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.